Thai hospital Bumrungrad International collaborates with genomics firms for research advancements

The hospital has partnered with BGI Shenzhen Co. Ltd. and Bangkok Genomics Innovation PLC.

Bumrungrad International Hospital has inked a memorandum of understanding (MoU) with Thai-based genomics research firms BGI Shenzhen Co. Ltd. and Bangkok Genomics Innovation PLC for genomics research.

Under the agreement, all entities involved will support the technological advancements through their specific expertise in genomic medicine, from patient diagnosis to treatments.

ALSO READ: NTUH partners with Guatemalan facility for maternal and paediatric care improvement

“Genomic medicine offers opportunities to understand diseases at their most fundamental level, tailor treatments to the individuals, and even anticipate health issues before they arise. The objective of having this strategic partnership will bring us closer to a future of predictive and preventative care,” Artirat Charukitpipat, CEO of Bumrungrad International Hospital, said.

Currently, Bumrungrad International Hospital stands as a leader in global healthcare and genomic medicine in Thailand through numerous efforts in research and clinical practice of genomic treatments.